Solara Active Pharma Sciences is a turnaround whose base business has reached a new operating level while the legacy ibuprofen drag has narrowed. The investment question is whether the base business can hold that level and whether the ibuprofen review can remove the remaining drag without a large capital loss.
Q2 FY27 was the strongest quarter in about five years. Revenue was INR418 crores, up 33% year-on-year; EBITDA was INR77 crores, up 118%; PAT was INR28.5 crores against a loss of about INR10 crores. The base business did the work: revenue of INR327 crores, up 37%, and EBITDA of INR77 crores, up 68%, at a 23.6% margin. Regulated markets were about 78% of revenue. Ibuprofen revenue was INR91 crores, up 21%, and the business was close to EBITDA breakeven after a roughly INR9 crore loss in Q1. In simple terms, the base business carried the consolidated EBITDA in Q2; the commodity business stopped subtracting from it.
The business economics are now clearer than at any point in the prior six quarters. The base business sells complex, small-volume APIs where regulatory qualification and chemistry capability limit competition. Management says the sustainable gross margin is 52-55%, and Q2 reported above 50%, or about 53% adjusted for raw-material pass-through. The operating cost base has been held near INR120 crores, so incremental gross margin has flowed to EBITDA. That is the operating leverage mechanism: higher base-business volume on a flat cost base. The Q2 EBITDA margin of 23.6% is still below the 25% plus or minus 1% target management gave in Q1 FY27, so there is room left, but the target has not been met.
Ibuprofen remains a different business. Q2 gross margin recovered to 36% from about 21% in Q1, but management attributed the improvement to market dynamics and customer price support rather than a structural cost fix. The process is roughly 20 years old, Solara is not backward integrated into IBAP, and it lacks the newer technologies competitors use. The business was close to breakeven in Q2, but management explicitly declined to guide Q3. The strategic review is now expected to close in about 12 weeks from October 2026, beyond the earlier H1 FY27 target. The options are unchanged: repurpose the plant into a multiproduct facility including intermediates, or sell it. Recovery of the roughly INR700 crores deployed capital is uncertain; the CFO said in Q1 FY27 that expecting the entire capital back would be slightly farfetched.
The earnings path therefore has two separate proofs. First, the base business must hold above INR300 crores a quarter and sustain the 52-55% gross margin as pass-through revenue fades. Q2 growth included about INR25-30 crores of consolidated revenue from price increases, so the underlying volume trajectory is lower than the reported 33% consolidated growth. The CFO said the West Asia input-cost headwind may last at least one to two more quarters. The second proof is the ibuprofen review: a decision that stops the capital drain and clarifies Vizag and CRAMS. Until that happens, consolidated results remain a blend of a mid-20s margin base business and a commodity business that can swing between breakeven and a INR10-15 crore quarterly loss.
Capital allocation is conservative. Solara is not building greenfield capacity; it is spending INR40-50 crores a year on maintenance and debottlenecking, with INR10-15 crores per quarter. Earlier disclosure put the FY27 debottlenecking component at about INR40 crores to lift high-margin line capacity 20-30% with a two-to-three-quarter payback, but the Q2 call did not update the split or the capacity target. Net debt was about INR500 crores at September 2026 and 1.8x EBITDA, down from INR614 crores in March 2026 but up about INR20 crores sequentially on working capital and maintenance capex. Net finance cost fell about 17% year-on-year on the lower debt. The FY29 net-debt-free target remains an aspiration; the earlier INR440 crores March 2027 intermediate target was not repeated.
Management delivery is mixed. The debt reduction and base-business revenue commitments have been met in direction. The FY26 EBITDA outlook was missed. The ibuprofen review has slipped from Q4 FY26 results to H1 FY27 to about 12 weeks from October 2026. The Vizag 5-6 month commercial-production commitment from February 2026 was abandoned within a quarter. The DMF filing restart is on track: two filed in FY27, five targeted, but management still expects new-product revenue only from FY29-30. Sandeep Rao's own test is appropriate: another two quarters in line with or better than Q2 before calling a turnaround.
The thesis is not that Solara is already a mid-20s EBITDA specialty API company. It is that the base business has demonstrated the revenue scale and gross-margin profile to become one, while the remaining obstacle is a commodity business whose review has a dated, near-term checkpoint. The falsifiers are concrete. A further delay or a large write-down in the ibuprofen review would leave the capital loss and the fixed-cost burden unresolved. Base-business growth below 10% or a gross margin that falls back toward the high-40s would show Q2 was mostly pass-through. A working-capital squeeze that keeps net debt near INR500 crores would delay the deleveraging path. And a failure to convert the five FY27 DMF filings into commercial approvals by FY29-30 would leave the new-product pipeline empty again. Q2 supports the first half of the thesis; it does not yet prove the second.
companyname: SOLARA ticker: SOLARA sector: Not classified Solara Active Pharma Sciences Limited is a pure-play Active Pharmaceutical Ingredient (API) manufacturer. The company designs and manufactures the active molecules that go into finished medicines, selling to generic and innovator pharmaceutical companies across more than 70 countries. It does not make finished dosage forms itself; it sits one step up the pharma value chain. The business was carved out of the Strides-Shasun group in 2018 ...
Read the full report →debt reduction
On the Q2 FY27 call, management guided to five DMF filings in FY27, with two filed and three more targeted before year-end; a base-business gross margin range of 52-55%; a broadly flat operating cost base within plus or minus 2-3%; annual capex of INR40-50 crores with INR10-15 crores per quarter; and conclusion of the ibuprofen strategic review in about 12 weeks. No explicit FY27 consolidated revenue or EBITDA guidance was issued.
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Solara Active Pharma Sciences Limited and 4,900+ companies.
5-day free pass. No card required.